Review



human adipose derived mesenchymal stem cells asc  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    ATCC human adipose derived mesenchymal stem cells asc
    Human Adipose Derived Mesenchymal Stem Cells Asc, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 241 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human adipose derived mesenchymal stem cells asc/product/ATCC
    Average 97 stars, based on 241 article reviews
    human adipose derived mesenchymal stem cells asc - by Bioz Stars, 2026-03
    97/100 stars

    Images



    Similar Products

    97
    ATCC human adipose derived mesenchymal stem cells asc
    Human Adipose Derived Mesenchymal Stem Cells Asc, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human adipose derived mesenchymal stem cells asc/product/ATCC
    Average 97 stars, based on 1 article reviews
    human adipose derived mesenchymal stem cells asc - by Bioz Stars, 2026-03
    97/100 stars
      Buy from Supplier

    94
    Sino Biological asc gfp
    Asc Gfp, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/asc gfp/product/Sino Biological
    Average 94 stars, based on 1 article reviews
    asc gfp - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    93
    MedChemExpress human asc protein
    Human Asc Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human asc protein/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    human asc protein - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    94
    Sino Biological asc
    Asc, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/asc/product/Sino Biological
    Average 94 stars, based on 1 article reviews
    asc - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    90
    Thermo Fisher anti-human itga3 antibody clone asc-1
    (a) Experimental design for the pull-down of Siglec-10 ligands on PDAC cells. Recombinant Siglec-10 (as well as no-protein control or Siglec-5 control) Fc was allowed to bind its physiological ligands on the surface of PDAC cells, followed by an HRP-conjugated anti-Fc secondary antibody. In the presence of H O, HRP generated short-lived radicals that facilitated the transfer of biotin to proximal Siglec-10 ligands. Biotinylated Siglec-10 ligands were pulled down using streptavidin beads and identified by mass spectrometry. (b) A total of 4,044 proteins were identified, with enriched binding compared to a control using the anti-Fc antibody only without Siglec-10 protein. Of these, 110 proteins showed enrichment relative to a Siglec-5 control. Six proteins—CD47, CD59, CD73, ITGB6, <t>ITGA3,</t> and ITGB1—were significantly overexpressed in PAAD tissues compared to normal tissues in the TCGA dataset. (c) Response curves showing interactions between Siglec-10 and the six glycoproteins measured by surface plasmon resonance (SPR). Two concentrations (1000 nM, green; 100 nM, red) were tested for all glycoproteins, while ITGA3 was also tested at 300 nM (green) and 30 nM (red). (d) Binding of the SNA lectin (specific for sialic acid) to ITGA3 and ITGB1 recombinant glycoproteins was measured by a lectin array. Sialidase-treated glycoproteins (red bars) showed significantly reduced binding compared to untreated glycoproteins (blue bars). Unpaired t-tests were used for statistical analyses. (e) SPR response curves comparing the binding of intact (sialylated) ITGA3 and desialylated ITGA3 to immobilized Siglec-10. (f) SPR response curves comparing the binding of intact (sialylated) ITGB1 and desialylated ITGB1 to immobilized Siglec-10.
    Anti Human Itga3 Antibody Clone Asc 1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-human itga3 antibody clone asc-1/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    anti-human itga3 antibody clone asc-1 - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    96
    ATCC normal human ascs
    <t>Human</t> <t>ASC</t> osteogenesis is supported by culture on SBG-PLGA composites and rhBMP-2 treatment. mRNA levels of the early and late osteoblastic markers, BMP-2 and Noggin ( NOG ) in human <t>ASCs</t> cultured on SBG-PLGA composites in ( A ), ( C ) standard osteogenic medium or ( B ), ( D ) standard osteogenic medium supplemented with 100 ng/ml rhBMP-2. Results are presented as relative mRNA expression levels vs. mRNA levels for ASCs cultured on a plain PLGA control (black line at 1). ( E ) Nitric oxide (NO) concentration in culture media after 24-h culture of ASC cells on SBG-PLGA composites in standard osteogenic medium. Averages ± SD are indicated. One-way or two-way ANOVA tests, * p < 0.05, ** p < 0.001, *** p < 0.0001 relative to the PLGA control group
    Normal Human Ascs, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/normal human ascs/product/ATCC
    Average 96 stars, based on 1 article reviews
    normal human ascs - by Bioz Stars, 2026-03
    96/100 stars
      Buy from Supplier

    96
    PromoCell human ascs
    <t>Human</t> <t>ASC</t> osteogenesis is supported by culture on SBG-PLGA composites and rhBMP-2 treatment. mRNA levels of the early and late osteoblastic markers, BMP-2 and Noggin ( NOG ) in human <t>ASCs</t> cultured on SBG-PLGA composites in ( A ), ( C ) standard osteogenic medium or ( B ), ( D ) standard osteogenic medium supplemented with 100 ng/ml rhBMP-2. Results are presented as relative mRNA expression levels vs. mRNA levels for ASCs cultured on a plain PLGA control (black line at 1). ( E ) Nitric oxide (NO) concentration in culture media after 24-h culture of ASC cells on SBG-PLGA composites in standard osteogenic medium. Averages ± SD are indicated. One-way or two-way ANOVA tests, * p < 0.05, ** p < 0.001, *** p < 0.0001 relative to the PLGA control group
    Human Ascs, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human ascs/product/PromoCell
    Average 96 stars, based on 1 article reviews
    human ascs - by Bioz Stars, 2026-03
    96/100 stars
      Buy from Supplier

    Image Search Results


    (a) Experimental design for the pull-down of Siglec-10 ligands on PDAC cells. Recombinant Siglec-10 (as well as no-protein control or Siglec-5 control) Fc was allowed to bind its physiological ligands on the surface of PDAC cells, followed by an HRP-conjugated anti-Fc secondary antibody. In the presence of H O, HRP generated short-lived radicals that facilitated the transfer of biotin to proximal Siglec-10 ligands. Biotinylated Siglec-10 ligands were pulled down using streptavidin beads and identified by mass spectrometry. (b) A total of 4,044 proteins were identified, with enriched binding compared to a control using the anti-Fc antibody only without Siglec-10 protein. Of these, 110 proteins showed enrichment relative to a Siglec-5 control. Six proteins—CD47, CD59, CD73, ITGB6, ITGA3, and ITGB1—were significantly overexpressed in PAAD tissues compared to normal tissues in the TCGA dataset. (c) Response curves showing interactions between Siglec-10 and the six glycoproteins measured by surface plasmon resonance (SPR). Two concentrations (1000 nM, green; 100 nM, red) were tested for all glycoproteins, while ITGA3 was also tested at 300 nM (green) and 30 nM (red). (d) Binding of the SNA lectin (specific for sialic acid) to ITGA3 and ITGB1 recombinant glycoproteins was measured by a lectin array. Sialidase-treated glycoproteins (red bars) showed significantly reduced binding compared to untreated glycoproteins (blue bars). Unpaired t-tests were used for statistical analyses. (e) SPR response curves comparing the binding of intact (sialylated) ITGA3 and desialylated ITGA3 to immobilized Siglec-10. (f) SPR response curves comparing the binding of intact (sialylated) ITGB1 and desialylated ITGB1 to immobilized Siglec-10.

    Journal: bioRxiv

    Article Title: Targeting Siglec-10/α3β1 Integrin Interactions Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer

    doi: 10.1101/2025.05.06.652455

    Figure Lengend Snippet: (a) Experimental design for the pull-down of Siglec-10 ligands on PDAC cells. Recombinant Siglec-10 (as well as no-protein control or Siglec-5 control) Fc was allowed to bind its physiological ligands on the surface of PDAC cells, followed by an HRP-conjugated anti-Fc secondary antibody. In the presence of H O, HRP generated short-lived radicals that facilitated the transfer of biotin to proximal Siglec-10 ligands. Biotinylated Siglec-10 ligands were pulled down using streptavidin beads and identified by mass spectrometry. (b) A total of 4,044 proteins were identified, with enriched binding compared to a control using the anti-Fc antibody only without Siglec-10 protein. Of these, 110 proteins showed enrichment relative to a Siglec-5 control. Six proteins—CD47, CD59, CD73, ITGB6, ITGA3, and ITGB1—were significantly overexpressed in PAAD tissues compared to normal tissues in the TCGA dataset. (c) Response curves showing interactions between Siglec-10 and the six glycoproteins measured by surface plasmon resonance (SPR). Two concentrations (1000 nM, green; 100 nM, red) were tested for all glycoproteins, while ITGA3 was also tested at 300 nM (green) and 30 nM (red). (d) Binding of the SNA lectin (specific for sialic acid) to ITGA3 and ITGB1 recombinant glycoproteins was measured by a lectin array. Sialidase-treated glycoproteins (red bars) showed significantly reduced binding compared to untreated glycoproteins (blue bars). Unpaired t-tests were used for statistical analyses. (e) SPR response curves comparing the binding of intact (sialylated) ITGA3 and desialylated ITGA3 to immobilized Siglec-10. (f) SPR response curves comparing the binding of intact (sialylated) ITGB1 and desialylated ITGB1 to immobilized Siglec-10.

    Article Snippet: PDAC cells were incubated with anti-human ITGA3 and ITGB1 antibodies (Clone ASC-1 and TS2/16, respectively, from Thermo Fisher Scientific) at a concentration of 1 μg/mL in 1× PBS at 4°C for 15 minutes.

    Techniques: Recombinant, Control, Generated, Mass Spectrometry, Binding Assay, SPR Assay

    (a) Flow cytometric analysis of ITGA3 expression on PDAC cell lines (HS766T, AsPC-1, and PANC-1) along the x-axis. (b) Comparative expression of ITGA3 in PAAD tissues versus normal tissues in the TCGA dataset. Unpaired t tests. * = P<0.05. (c) Flow cytometric analysis of ITGB1 expression on PDAC cell lines (HS766T, AsPC-1, and PANC-1) along the x-axis. (d) Comparative expression of ITGB1 in PAAD tissues versus normal tissues in the TCGA dataset. Unpaired t tests. * = P<0.05. (e–g) Survival analysis of pancreatic tumor patients in the TCGA dataset showing the correlation between (e) CD24, (f) ITGA3, and (g) ITGB1 expression on overall survival. (h) Single-cell RNA-seq analysis of publicly available datasets using BBrowser software. Clusters representing distinct cell types were categorized into normal (blue clusters) and PDAC (orange clusters). (i) ITGA3 expression levels in epithelial cell clusters from normal tissues (blue bar) and PDAC tissues (orange bar). The intensity of red represents the expression of ITGA3, with darker shades indicating higher expression levels. Mann Whitney u test was used for statistical analysis. (j) Pathway analysis comparing ITGA3 hi and ITGA3 low epithelial cells in PDAC tissues to identify upregulated and downregulated pathways. (k) ITGB1 expression levels in epithelial cell clusters from normal tissues (blue bar) and PDAC tissues (orange bar). The intensity of red represents the expression of ITGB1, with darker shades indicating higher expression levels. Mann Whitney u test was used for statistical analysis.

    Journal: bioRxiv

    Article Title: Targeting Siglec-10/α3β1 Integrin Interactions Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer

    doi: 10.1101/2025.05.06.652455

    Figure Lengend Snippet: (a) Flow cytometric analysis of ITGA3 expression on PDAC cell lines (HS766T, AsPC-1, and PANC-1) along the x-axis. (b) Comparative expression of ITGA3 in PAAD tissues versus normal tissues in the TCGA dataset. Unpaired t tests. * = P<0.05. (c) Flow cytometric analysis of ITGB1 expression on PDAC cell lines (HS766T, AsPC-1, and PANC-1) along the x-axis. (d) Comparative expression of ITGB1 in PAAD tissues versus normal tissues in the TCGA dataset. Unpaired t tests. * = P<0.05. (e–g) Survival analysis of pancreatic tumor patients in the TCGA dataset showing the correlation between (e) CD24, (f) ITGA3, and (g) ITGB1 expression on overall survival. (h) Single-cell RNA-seq analysis of publicly available datasets using BBrowser software. Clusters representing distinct cell types were categorized into normal (blue clusters) and PDAC (orange clusters). (i) ITGA3 expression levels in epithelial cell clusters from normal tissues (blue bar) and PDAC tissues (orange bar). The intensity of red represents the expression of ITGA3, with darker shades indicating higher expression levels. Mann Whitney u test was used for statistical analysis. (j) Pathway analysis comparing ITGA3 hi and ITGA3 low epithelial cells in PDAC tissues to identify upregulated and downregulated pathways. (k) ITGB1 expression levels in epithelial cell clusters from normal tissues (blue bar) and PDAC tissues (orange bar). The intensity of red represents the expression of ITGB1, with darker shades indicating higher expression levels. Mann Whitney u test was used for statistical analysis.

    Article Snippet: PDAC cells were incubated with anti-human ITGA3 and ITGB1 antibodies (Clone ASC-1 and TS2/16, respectively, from Thermo Fisher Scientific) at a concentration of 1 μg/mL in 1× PBS at 4°C for 15 minutes.

    Techniques: Expressing, RNA Sequencing, Software, MANN-WHITNEY

    (a) Schematic representation of the experimental setup to enrich for ITGA3 low or ITGB1 low PDAC cells. Columns coated with anti-ITGA3 or anti-ITGB1 antibodies were used to isolate ITGA3 low or ITGB1 low cells (cells passing through the columns without binding), respectively. Cells passing through uncoated columns (expressing high levels of ITGA3 or ITGB1) were used as controls. (b) Representative flow cytometry analysis showing the expression of ITGA3 (left) or Siglec-10 ligands (right) expression levels on MIA PaCa-2 cells, depleted from ITGA3 hi cells (ITGA3 low ) or not (control cells; Ctrl cells). (c) Schematic representation of the experimental setup to test the phagocytic capacity of monocyte-derived macrophages targeting control cells (enriched with ITGA3 hi cells) or ITGA3 low cells (n = 4–6). (d-e) Phagocytosis of control and ITGA3 low MIA PaCa-2 (c) or PANC1 (d) PDAC cells by macrophages from different donors. Top: Representative images where increased red indicates higher phagocytosis. Bottom left: Live imaging results (each symbol represents data from one donor). Bottom right: Area under the curve (AUC) data compiled from multiple donors. Statistical significance was assessed using ratio paired t-tests. (f) Schematic representation of the experimental setup to test the phagocytic capacity of monocyte-derived macrophages targeting control cells (enriched with ITGB1 hi cells) or ITGB1 low cells (n = 4–6). (g-h) Phagocytosis of control and ITGB1 low MIA PaCa-2 (f) or PANC1 (g) PDAC cells by macrophages from different donors. Top: Representative images showing phagocytosis (increased red indicates higher phagocytosis). Bottom left: Live imaging results (each symbol represents data from one donor). Bottom right: AUC data compiled from multiple donors. Statistical significance was assessed using ratio paired t-tests.

    Journal: bioRxiv

    Article Title: Targeting Siglec-10/α3β1 Integrin Interactions Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer

    doi: 10.1101/2025.05.06.652455

    Figure Lengend Snippet: (a) Schematic representation of the experimental setup to enrich for ITGA3 low or ITGB1 low PDAC cells. Columns coated with anti-ITGA3 or anti-ITGB1 antibodies were used to isolate ITGA3 low or ITGB1 low cells (cells passing through the columns without binding), respectively. Cells passing through uncoated columns (expressing high levels of ITGA3 or ITGB1) were used as controls. (b) Representative flow cytometry analysis showing the expression of ITGA3 (left) or Siglec-10 ligands (right) expression levels on MIA PaCa-2 cells, depleted from ITGA3 hi cells (ITGA3 low ) or not (control cells; Ctrl cells). (c) Schematic representation of the experimental setup to test the phagocytic capacity of monocyte-derived macrophages targeting control cells (enriched with ITGA3 hi cells) or ITGA3 low cells (n = 4–6). (d-e) Phagocytosis of control and ITGA3 low MIA PaCa-2 (c) or PANC1 (d) PDAC cells by macrophages from different donors. Top: Representative images where increased red indicates higher phagocytosis. Bottom left: Live imaging results (each symbol represents data from one donor). Bottom right: Area under the curve (AUC) data compiled from multiple donors. Statistical significance was assessed using ratio paired t-tests. (f) Schematic representation of the experimental setup to test the phagocytic capacity of monocyte-derived macrophages targeting control cells (enriched with ITGB1 hi cells) or ITGB1 low cells (n = 4–6). (g-h) Phagocytosis of control and ITGB1 low MIA PaCa-2 (f) or PANC1 (g) PDAC cells by macrophages from different donors. Top: Representative images showing phagocytosis (increased red indicates higher phagocytosis). Bottom left: Live imaging results (each symbol represents data from one donor). Bottom right: AUC data compiled from multiple donors. Statistical significance was assessed using ratio paired t-tests.

    Article Snippet: PDAC cells were incubated with anti-human ITGA3 and ITGB1 antibodies (Clone ASC-1 and TS2/16, respectively, from Thermo Fisher Scientific) at a concentration of 1 μg/mL in 1× PBS at 4°C for 15 minutes.

    Techniques: Binding Assay, Expressing, Flow Cytometry, Control, Derivative Assay, Imaging

    (a) Model illustrating the mechanism of Siglec-10-mediated inhibition of macrophage phagocytosis. Siglec-10 expressed on macrophages binds to its glycan ligands on PDAC cells, which are present on multiple proteins such as ITGA3, ITGB1, and CD24. This interaction induces inhibitory signaling in macrophages, suppressing phagocytosis (left panel). Blocking Siglec-10 with an antibody prevents inhibitory signaling, thereby enhancing macrophage phagocytic ability (right panel). (b) Screening of recombinant antibodies from the top clones for Siglec-10 binding using ELISA. Binding to immobilized Siglec-10 (blue) and Siglec-5 (gray) proteins is shown. (c) Flow cytometric analysis of clone selectivity, showing binding to CHO-K1 cells expressing either Siglec-10 (blue) or Siglec-5 (gray). (d) Area under the curve (AUC) analysis of an in vitro phagocytosis assay to screen the ability of Siglec-10 antibody clones, as well as the commercially available antibodies against CD24 and Siglec-10, to enhance the phagocytic activity of macrophages against AsPC-1 PDAC cells. (e) AUC analysis of the in vitro phagocytosis assay for the top-performing Siglec-10 antibody clone using macrophages differentiated from the monocytes of four donors. Statistical significance was determined using Friedman’s ANOVA test. (f) Time-course analysis of the in vitro phagocytosis assay for the top Siglec-10 blocking antibody clone (68A11A1, blue) compared to the isotype control (gray). Results are based on n=4 independent experiments. (g) ELISA-based binding analysis of the 68A11A1 recombinant antibody to immobilized recombinant Siglec-10 and Siglec-5 proteins at different dilutions. (h) Evaluation of the ability of anti-CD24 or recombinant Siglec-10 antibody (clone 68A11A1) to enhance macrophage-mediated phagocytosis of several PDAC cell lines (AsPC-1, MIA PaCa-2, and PANC-1). Phagocytosis was normalized to the isotype control for each antibody and conducted using macrophages differentiated from monocytes of 5–8 healthy donors. Each symbol represents data from an individual donor, and statistical analyses were performed using ratio paired t-tests compared to the isotype control. On the right, a representative image of the killing assays is shown (red indicates increased killing).

    Journal: bioRxiv

    Article Title: Targeting Siglec-10/α3β1 Integrin Interactions Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer

    doi: 10.1101/2025.05.06.652455

    Figure Lengend Snippet: (a) Model illustrating the mechanism of Siglec-10-mediated inhibition of macrophage phagocytosis. Siglec-10 expressed on macrophages binds to its glycan ligands on PDAC cells, which are present on multiple proteins such as ITGA3, ITGB1, and CD24. This interaction induces inhibitory signaling in macrophages, suppressing phagocytosis (left panel). Blocking Siglec-10 with an antibody prevents inhibitory signaling, thereby enhancing macrophage phagocytic ability (right panel). (b) Screening of recombinant antibodies from the top clones for Siglec-10 binding using ELISA. Binding to immobilized Siglec-10 (blue) and Siglec-5 (gray) proteins is shown. (c) Flow cytometric analysis of clone selectivity, showing binding to CHO-K1 cells expressing either Siglec-10 (blue) or Siglec-5 (gray). (d) Area under the curve (AUC) analysis of an in vitro phagocytosis assay to screen the ability of Siglec-10 antibody clones, as well as the commercially available antibodies against CD24 and Siglec-10, to enhance the phagocytic activity of macrophages against AsPC-1 PDAC cells. (e) AUC analysis of the in vitro phagocytosis assay for the top-performing Siglec-10 antibody clone using macrophages differentiated from the monocytes of four donors. Statistical significance was determined using Friedman’s ANOVA test. (f) Time-course analysis of the in vitro phagocytosis assay for the top Siglec-10 blocking antibody clone (68A11A1, blue) compared to the isotype control (gray). Results are based on n=4 independent experiments. (g) ELISA-based binding analysis of the 68A11A1 recombinant antibody to immobilized recombinant Siglec-10 and Siglec-5 proteins at different dilutions. (h) Evaluation of the ability of anti-CD24 or recombinant Siglec-10 antibody (clone 68A11A1) to enhance macrophage-mediated phagocytosis of several PDAC cell lines (AsPC-1, MIA PaCa-2, and PANC-1). Phagocytosis was normalized to the isotype control for each antibody and conducted using macrophages differentiated from monocytes of 5–8 healthy donors. Each symbol represents data from an individual donor, and statistical analyses were performed using ratio paired t-tests compared to the isotype control. On the right, a representative image of the killing assays is shown (red indicates increased killing).

    Article Snippet: PDAC cells were incubated with anti-human ITGA3 and ITGB1 antibodies (Clone ASC-1 and TS2/16, respectively, from Thermo Fisher Scientific) at a concentration of 1 μg/mL in 1× PBS at 4°C for 15 minutes.

    Techniques: Inhibition, Glycoproteomics, Blocking Assay, Recombinant, Clone Assay, Binding Assay, Enzyme-linked Immunosorbent Assay, Expressing, In Vitro, Phagocytosis Assay, Activity Assay, Control

    Human ASC osteogenesis is supported by culture on SBG-PLGA composites and rhBMP-2 treatment. mRNA levels of the early and late osteoblastic markers, BMP-2 and Noggin ( NOG ) in human ASCs cultured on SBG-PLGA composites in ( A ), ( C ) standard osteogenic medium or ( B ), ( D ) standard osteogenic medium supplemented with 100 ng/ml rhBMP-2. Results are presented as relative mRNA expression levels vs. mRNA levels for ASCs cultured on a plain PLGA control (black line at 1). ( E ) Nitric oxide (NO) concentration in culture media after 24-h culture of ASC cells on SBG-PLGA composites in standard osteogenic medium. Averages ± SD are indicated. One-way or two-way ANOVA tests, * p < 0.05, ** p < 0.001, *** p < 0.0001 relative to the PLGA control group

    Journal: Journal of Biological Engineering

    Article Title: Rapid osteoinduction of human adipose-derived stem cells grown on bioactive surfaces and stimulated by chemically modified media flow

    doi: 10.1186/s13036-025-00491-2

    Figure Lengend Snippet: Human ASC osteogenesis is supported by culture on SBG-PLGA composites and rhBMP-2 treatment. mRNA levels of the early and late osteoblastic markers, BMP-2 and Noggin ( NOG ) in human ASCs cultured on SBG-PLGA composites in ( A ), ( C ) standard osteogenic medium or ( B ), ( D ) standard osteogenic medium supplemented with 100 ng/ml rhBMP-2. Results are presented as relative mRNA expression levels vs. mRNA levels for ASCs cultured on a plain PLGA control (black line at 1). ( E ) Nitric oxide (NO) concentration in culture media after 24-h culture of ASC cells on SBG-PLGA composites in standard osteogenic medium. Averages ± SD are indicated. One-way or two-way ANOVA tests, * p < 0.05, ** p < 0.001, *** p < 0.0001 relative to the PLGA control group

    Article Snippet: ASC52telo cells (ASC; ATCC, SCRC-4000) and normal human ASCs (ATCC, PCS-500-011) were expanded in the dedicated medium (ATCC, Mesenchymal Stem Cell Basal Medium with Mesenchymal Stem Cell Growth Kit and G418).

    Techniques: Cell Culture, Expressing, Control, Concentration Assay

    Cumulative osteogenic effect of Phenamil and PD98059 treatment in rhBMP-2 stimulated human ASCs cultured on SBG-PLGA composites. mRNA levels of osteoblastic markers in ( A ) 7-day and ( B ) 21-day ASC cultures on SBG-PLGA composites. ASCs were cultured in osteogenic medium supplemented with 100 ng/ml rhBMP-2 or 100 ng/ml rhBMP-2, 50 µM PD98059 and 20 µM Phenamil. Results are presented as relative mRNA expression compared to mRNA levels in control cells cultured on PLGA with rhBMP-2 only (marked as black line at 1). ( C ) mRNA levels of selected osteoblastic markers in 3-day osteogenic ASC cultures treated with different doses of rhBMP-2 (25–250 ng/ml), Phenamil (5–50 µM) or PD98059 (1-125 µM); under fluid shear stress. Results are presented as the expression relative to osteogenic cultures treated only with ascorbic acid, dexamethasone and β-glycerophosphate. ( D ) Graphical hypothesis of BMP-2, PD98059 and Phenamil cross-talk in intracellular signaling. Average values ± SD are indicated. Two-way ANOVA test, * p < 0.05, ** p < 0.001, *** p < 0.0001 relative to the PLGA control group or between marked groups. BMP-2 – bone morphogenetic protein 2, OC – osteocalcin, ON – osteonectin, FOS – AP-1 transcription factor subunit (c-fos), OPG – osteoprotegerin

    Journal: Journal of Biological Engineering

    Article Title: Rapid osteoinduction of human adipose-derived stem cells grown on bioactive surfaces and stimulated by chemically modified media flow

    doi: 10.1186/s13036-025-00491-2

    Figure Lengend Snippet: Cumulative osteogenic effect of Phenamil and PD98059 treatment in rhBMP-2 stimulated human ASCs cultured on SBG-PLGA composites. mRNA levels of osteoblastic markers in ( A ) 7-day and ( B ) 21-day ASC cultures on SBG-PLGA composites. ASCs were cultured in osteogenic medium supplemented with 100 ng/ml rhBMP-2 or 100 ng/ml rhBMP-2, 50 µM PD98059 and 20 µM Phenamil. Results are presented as relative mRNA expression compared to mRNA levels in control cells cultured on PLGA with rhBMP-2 only (marked as black line at 1). ( C ) mRNA levels of selected osteoblastic markers in 3-day osteogenic ASC cultures treated with different doses of rhBMP-2 (25–250 ng/ml), Phenamil (5–50 µM) or PD98059 (1-125 µM); under fluid shear stress. Results are presented as the expression relative to osteogenic cultures treated only with ascorbic acid, dexamethasone and β-glycerophosphate. ( D ) Graphical hypothesis of BMP-2, PD98059 and Phenamil cross-talk in intracellular signaling. Average values ± SD are indicated. Two-way ANOVA test, * p < 0.05, ** p < 0.001, *** p < 0.0001 relative to the PLGA control group or between marked groups. BMP-2 – bone morphogenetic protein 2, OC – osteocalcin, ON – osteonectin, FOS – AP-1 transcription factor subunit (c-fos), OPG – osteoprotegerin

    Article Snippet: ASC52telo cells (ASC; ATCC, SCRC-4000) and normal human ASCs (ATCC, PCS-500-011) were expanded in the dedicated medium (ATCC, Mesenchymal Stem Cell Basal Medium with Mesenchymal Stem Cell Growth Kit and G418).

    Techniques: Cell Culture, Expressing, Control, Shear

    Fluid shear stress strengthens the osteogenic effects of rhBMP-2, PD98059 and Phenamil in ASCs cultured on SBG-PLGA composites. mRNA levels of osteoblastic markers after 7-day ASC culture on SBG-PLGA composites in ( A ) standard osteogenic medium under either static conditions or with fluid shear stress; and ( C ) osteogenic medium supplemented with 100 ng/ml rhBMP-2, 50 µM PD98059 and 20 µM Phenamil under either static conditions or with fluid shear stress. Results are presented as relative mRNA expression levels compared to mRNA levels in a control, static culture on PLGA (marked as a black line at 1). ( B ) The method of fluid shear stress application in ASC cultures using a standard laboratory see-saw rocker (7° tilt angle, 6 RPM frequency). ( D ) F-actin distribution in ASCs (Phalloidin-Atto488, magenta colored) at day 3 of culture in osteogenic medium supplemented with rhBMP-2, PD98059 and Phenamil after continuous static or dynamic culture conditions applied for 3 days. Scale bar represents 100 μm. ( E ) Western blot (WB) analysis of p-ERK1/2 and p-SMAD1/5/8 in ASCs after 1-h treatment with rhBMP-2 or rhBMP-2, PD98059 and Phenamil in static or dynamic conditions (upper panel) along with densitometric quantifications of WB results normalized to GAPDH levels. Averages ± SD are indicated. Two-way ANOVA test, * p < 0.05, ** p < 0.001, *** p < 0.0001 relative to the static PLGA control or between marked groups

    Journal: Journal of Biological Engineering

    Article Title: Rapid osteoinduction of human adipose-derived stem cells grown on bioactive surfaces and stimulated by chemically modified media flow

    doi: 10.1186/s13036-025-00491-2

    Figure Lengend Snippet: Fluid shear stress strengthens the osteogenic effects of rhBMP-2, PD98059 and Phenamil in ASCs cultured on SBG-PLGA composites. mRNA levels of osteoblastic markers after 7-day ASC culture on SBG-PLGA composites in ( A ) standard osteogenic medium under either static conditions or with fluid shear stress; and ( C ) osteogenic medium supplemented with 100 ng/ml rhBMP-2, 50 µM PD98059 and 20 µM Phenamil under either static conditions or with fluid shear stress. Results are presented as relative mRNA expression levels compared to mRNA levels in a control, static culture on PLGA (marked as a black line at 1). ( B ) The method of fluid shear stress application in ASC cultures using a standard laboratory see-saw rocker (7° tilt angle, 6 RPM frequency). ( D ) F-actin distribution in ASCs (Phalloidin-Atto488, magenta colored) at day 3 of culture in osteogenic medium supplemented with rhBMP-2, PD98059 and Phenamil after continuous static or dynamic culture conditions applied for 3 days. Scale bar represents 100 μm. ( E ) Western blot (WB) analysis of p-ERK1/2 and p-SMAD1/5/8 in ASCs after 1-h treatment with rhBMP-2 or rhBMP-2, PD98059 and Phenamil in static or dynamic conditions (upper panel) along with densitometric quantifications of WB results normalized to GAPDH levels. Averages ± SD are indicated. Two-way ANOVA test, * p < 0.05, ** p < 0.001, *** p < 0.0001 relative to the static PLGA control or between marked groups

    Article Snippet: ASC52telo cells (ASC; ATCC, SCRC-4000) and normal human ASCs (ATCC, PCS-500-011) were expanded in the dedicated medium (ATCC, Mesenchymal Stem Cell Basal Medium with Mesenchymal Stem Cell Growth Kit and G418).

    Techniques: Shear, Cell Culture, Expressing, Control, Western Blot

    Zinc (ZnO) or strontium (SrO) modified SBG-PLGA composites combined with fluid shear stress and BMP-based chemical stimulation, further increase osteogenic markers expression in early ASC cultures. mRNA levels of osteoblastic markers in ( A ) 3-day and ( B ) 6-day osteogenic ASC cultures on PLGA-based composites containing either unmodified or SrO- or ZnO-modified SBGs. Cells were treated with a combination of rhBMP-2, PD98059 and Phenamil at the indicated culture times in either static cultures or under fluid shear stress. Upper panels show the schemes of the ASC treatments. Results are presented as relative mRNA expression levels vs. mRNA levels in a control, static culture on PLGA (marked as a black line at 1). ( C ) Western blot (WB) analysis of phospho-β-catenin(Ser552), COX-2 and phospho-CREB(Ser133) levels in ASCs after 1-h treatment with rhBMP-2 or rhBMP-2, PD98059 and Phenamil in static or dynamic conditions (left panel) along with densitometric quantifications of WB results normalized to GAPDH levels (right panel). ( D ) Hypothesized signaling pathways involved in osteogenic response to treatment strategy. Averages ± SD are indicated. Two-way ANOVA test, * p < 0.05, ** p < 0.001, *** p < 0.0001 relative to the respective static PLGA control group or between marked groups

    Journal: Journal of Biological Engineering

    Article Title: Rapid osteoinduction of human adipose-derived stem cells grown on bioactive surfaces and stimulated by chemically modified media flow

    doi: 10.1186/s13036-025-00491-2

    Figure Lengend Snippet: Zinc (ZnO) or strontium (SrO) modified SBG-PLGA composites combined with fluid shear stress and BMP-based chemical stimulation, further increase osteogenic markers expression in early ASC cultures. mRNA levels of osteoblastic markers in ( A ) 3-day and ( B ) 6-day osteogenic ASC cultures on PLGA-based composites containing either unmodified or SrO- or ZnO-modified SBGs. Cells were treated with a combination of rhBMP-2, PD98059 and Phenamil at the indicated culture times in either static cultures or under fluid shear stress. Upper panels show the schemes of the ASC treatments. Results are presented as relative mRNA expression levels vs. mRNA levels in a control, static culture on PLGA (marked as a black line at 1). ( C ) Western blot (WB) analysis of phospho-β-catenin(Ser552), COX-2 and phospho-CREB(Ser133) levels in ASCs after 1-h treatment with rhBMP-2 or rhBMP-2, PD98059 and Phenamil in static or dynamic conditions (left panel) along with densitometric quantifications of WB results normalized to GAPDH levels (right panel). ( D ) Hypothesized signaling pathways involved in osteogenic response to treatment strategy. Averages ± SD are indicated. Two-way ANOVA test, * p < 0.05, ** p < 0.001, *** p < 0.0001 relative to the respective static PLGA control group or between marked groups

    Article Snippet: ASC52telo cells (ASC; ATCC, SCRC-4000) and normal human ASCs (ATCC, PCS-500-011) were expanded in the dedicated medium (ATCC, Mesenchymal Stem Cell Basal Medium with Mesenchymal Stem Cell Growth Kit and G418).

    Techniques: Modification, Shear, Expressing, Control, Western Blot, Protein-Protein interactions